Transgene recieves approval to start a Phase I trial of TG6050 15
Category: dates
Transgene announces Financial Calendar for 2023
Transgene announces Financial Calendar for 2023 15
Transgene Announces Upcoming Investor Meetings
Transgene announces upcoming investor meetings
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene reports business update and Q3 2022 financial position
TRANSGENE reports business update and Q3 2022 financial position
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
TRANSGENE R&D DAY
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
V. Moreno et al. ESMO 2022 Download the poster here Poster Presentation
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
2022 Half-year results and business update
